For many children, asthma can be a constant specter, with attacks at the most inconvenient and terrifying times. New research has now found that one inhaler containing two drugs can cut the risk of ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

Please provide your email address to receive an email when new articles are posted on . The meta-analysis included 27 unique randomized controlled trials and 50,496 patients. Combinations improved ...

Asthma-inhaler-resize_G_514410525 The SYGMA trials assessed the use of an as-needed combined corticosteroid/beta-agonist inhaler in patients with mild asthma. Level 2 ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...

In the first randomised controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Please provide your email address to receive an email when new articles are posted on . DALLAS — Single combination inhaler treatment with budesonide-formoterol on an as-needed basis, compared with ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

In asthma, the combination is indicated for adults and kids ages 6 and older to prevent symptoms (not for acute attacks); in COPD, the inhaler is approved as a maintenance treatment to improve ...

Ritedose Pharmaceuticals, a division of The Ritedose Corporation, has secured Food and Drug Administration approval for formoterol fumarate inhalation solution (20 mcg/2 ml). “The approval further ...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced the launch of DUAKLIR® PRESSAIR® (aclidinium bromide and formoterol fumarate) for the ...

Napa, CA (October 24, 2007) – Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), ...